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Pomen and Ischemic Heart Disease
athophysiologic Implications From the Women’s Ischemia
yndrome Evaluation (WISE) Study and Future Research Steps
rshed A. Quyyumi, MD, FRCP
tlanta, Georgia
The current review highlights gender-specific issues in ischemic heart disease (IHD)
presentation, evaluation, and outcomes with a special focus on the results derived from the
National Institutes of Health-National Heart, Lung, and Blood Institute–sponsored Wom-
en’s Ischemia Syndrome Evaluation (WISE) study. New evidence on gender-based differ-
ences in vascular wall, atherosclerotic plaque deposition, pathophysiology, and innovative
cardiovascular imaging techniques are reviewed. Critical areas of further inquiry needed to
advance new gender-specific IHD understanding are detailed. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.07566S–71S) © 2006 by the American College of Cardiology Foundation
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cecent observations pertaining to the diagnosis, prevalence,
nd progression of coronary artery disease (CAD) in women
ave increased the debate and controversy surrounding this
ondition that afflicts the vast majority of women living in
he western hemisphere and is the predominant cause of
heir morbidity and mortality. It has been convincingly
emonstrated that the incidence of CAD is lower in women
han in men for all age groups except the very elderly. This
as been offered as an explanation for the chronically
educed rate of diagnosis of underlying CAD in women
ither in its chronic stable state or in the setting of acute
oronary syndromes (1). Yet it has also been shown, as
ecently reported from the Women’s Ischemia Syndrome
valuation (WISE) study database, that nearly 60% of
omen undergoing invasive evaluation for investigation of
hest pain or abnormal noninvasive tests do not have any
ow-limiting coronary stenoses at angiography. Thus, it
ppears that misdiagnosis of CAD and acute coronary
vents on the one hand, and an often inappropriate overuse
f coronary angiography on the other, arises from the
nderappreciation by the medical community of the atypical
ymptomatic nature of presentation of CAD in women.
he problem does not resolve, however, once the results of
oronary angiography are available, as clearly demonstrated
y the careful follow-up of such women in the WISE II
tudy cohort. Even women found not to have significant
oronary luminal narrowing suffered persistent or worsening
ymptoms, often demonstrated test abnormalities that im-
licated an ischemic etiology for their symptoms, were
requently chronically disabled, consumed tremendous
ealth care resources, and, most importantly, experienced
dverse cardiovascular events during medium-term follow
p extending over a period of 4 to 5 years (2).
Thus, the challenges in understanding the manifestations
f CAD in women include: 1) better understanding of the
omplexity of presenting symptoms that appear to be
From the Emory University School of Medicine, Atlanta, Georgia.p
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004.ender-specific; 2) defining appropriate noninvasive tests
hat should identify not only those with obstructive CAD
ut also the subset with normal coronary arteries who are at
ncreased risk of cardiovascular event; and 3) understanding
f the gender-specific pathophysiology of chest pain, isch-
mia, disability, and factors determining progression from
inimal atherosclerosis to ischemic events. This task can
nly be accomplished by the discovery and adaptation of
adically different approaches to diagnosis and management
f cardiovascular diseases in women when appropriate. The
tandard approach of symptomatic presentation leading to
tress testing, coronary angiography, and lesion-specific
herapy, although reasonable in those with obstructive
AD, may not be appropriate for all women. Findings from
he WISE studies have highlighted the pathophysiologic
ole of microvascular dysfunction, subendocardial ischemia,
nflammation, genetic predisposition, and neurohormonal
mbalance in imparting risk.
yocardial ischemia and microvascular dysfunction. Al-
hough women undergoing coronary angiography present
ith chest pain suggestive of angina pectoris, it is clear that
p to 50% of them will have normal or insignificant CAD,
s compared to a 17% incidence in men (3). Yet a majority
f these women also have abnormal stress tests that include
ither ST-segment depression during exercise, perfusion
efects during radionuclide scintigraphy, or stress-induced
all motion abnormalities. This has given rise to the
oncept that these women have myocardial ischemia as a
esult of microvascular disease or dysfunction. However, the
vidence for this in the vast majority of women presenting
ith chest pain has been missing and largely arises from
tress tests that lack sufficient specificity (4). In fact studies
ave suggested that chest pain in many women is accom-
anied by a lowered pain threshold that may improve with
mipramine therapy (5).
There is nevertheless evidence for myocardial ischemia in
pproximately 20% of women with chest pain and normal
oronary arteries. Recent innovations in the application of
hosphorus-31 nuclear magnetic resonance spectroscopy
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yocardial high-energy phosphates, phosphocreatine, and
denosine triphosphate after stress. The WISE study inves-
igators have shown a transient decrease in myocardial
hosphocreatine/adenosine triphosphate ratio during hand-
rip exercise, indicating a shift toward anaerobic metabo-
ism or myocardial ischemia in 20% of women with chest
ain but no CAD (6). Subsequent three-year follow-up of
4 women with abnormal spectroscopy without CAD
emonstrated an event rate similar to that observed in
omen with CAD and considerably worse than those with
ormal coronaries and normal spectroscopy (7).
The reasons for the development of ischemia with min-
mal exercise remain unknown. It is clear that focal epicar-
ial spasm originally described by Prinzmetal et al. (8)
ccounts for 1% of ischemia in women undergoing an-
iography in the West. Vascular testing has revealed both
icrovascular smooth muscle dysfunction using adenosine
r nitroprusside infusions and endothelial dysfunction using
cetylcholine in 54% of the individuals (9), findings that
ppear to have prognostic value, as discussed in the follow-
ng text. Thus, further investigations into the mechanisms
nderlying phosphocreatine uptake abnormalities despite
ack of obstructive epicardial disease are warranted.
isk factors and vascular disease. There is incontrovert-
ble evidence to indicate that conventional risk factors for
therosclerosis account for the vast majority of the incident
AD observed in both men and women (10). However, it
s also clear that knowledge of the presence or absence of
hese factors in an individual does not help precisely predict
ither the presence or extent of CAD, nor the future
ccurrence of adverse cardiovascular outcomes. This may be
artly because the impact of risk factors in different indi-
iduals is variable and dependent on indeterminate factors
uch as duration of exposure and differing susceptibility.
nderstanding of the mechanisms underlying risk factor-
ediated vascular injury has allowed us to develop tools to
ore accurately define risk in individual patients.
xidative stress. One proposed unifying mechanism ex-
laining how disparate risk factors lead to CAD is oxidative
tress, which occurs when the production of cellular oxi-
ants exceeds the capacity of cellular antioxidant defense
echanisms (11). Virtually all of the known risk factors for
therosclerosis increase the production of reactive oxygen
pecies in the vascular wall. Oxidative stress leads to
ndothelial dysfunction which in turn induces vascular
Abbreviations and Acronyms
CHD  coronary heart disease
CRP  C-reactive protein
DASI  Duke Activity Status Index
EPC  endothelial progenitor cell
IHD  ischemic heart disease
WISE  Women’s Ischemia Syndrome Evaluationnflammation that may promote further oxidative stress in a beed-forward fashion ultimately leading to atherosclerosis
12). Therefore, it is not surprising that markers of oxidative
tress are proving to be early predictors not only of athero-
clerotic vascular disease (13–16) but also of long-term
rognosis (17,18). Serum and plasma myeloperoxidase
15,19), and isoprostane measurements appear to be impor-
ant prognostic markers. Moreover, the redox state of
ommon thiols, such as glutathione and cysteine, and
easures of lipid peroxidation in the blood stream strongly
nd independently correlate with carotid intima-media
hickening and endothelial dysfunction (20–22). Future
tudies evaluating risk of vascular disease in women should
ntegrate these novel markers of oxidative stress.
ndothelial function. The term “endothelial function”
efers to a multitude of physiologic functions of the vascular
ndothelium that maintain healthy homeostasis of the
ascular wall, including normal vasomotion, inhibition of
latelet aggregation and thrombus generation, and mainte-
ance of relative impermeability. Cardiovascular risk factors
ctivate a number of pro-oxidative processes that reduce the
ioavailability of nitric oxide as part of the transition from
ormal endothelial function to endothelial dysfunction (23–
5). Almost all conventional risk factors for atherosclerosis
re associated with endothelial dysfunction. These include
edentary lifestyle and obesity, hypercholesterolemia, hyper-
omocysteinemia, hypertension, diabetes, insulin resistance,
moking, and aging. Thus, the concept has been forwarded
hat endothelial vasodilator function is a reflection of the
verall vascular health. Indeed, several studies in predomi-
antly male populations demonstrated that endothelium-
ependent vasomotor function of the coronary/brachial
rteries predicted long-term cardiovascular risk, including
cute cardiac and cerebrovascular events and development of
ypertension (26–28).
The WISE study investigators studied coronary vascular
ndothelium-dependent and -independent function using
ntracoronary acetylcholine and nitroglycerin, respectively,
n 163 women undergoing angiography. Almost 75% of the
omen had mild or no angiographic CAD, and during a
our-year follow-up cardiovascular events were indepen-
ently predicted by coronary vascular endothelial function
ndependent of risk factors and extent of CAD (9). These
ata not only demonstrate that assessment of vascular
ndothelial function can provide an excellent prognostic tool
n such women but also raise a couple of questions. First,
oes endothelial function predict outcome only in women
ith mild or no angiographic disease, or will this also apply
o a larger group of women with and without risk factors or
o those with extensive disease? Second, can endothelial
unction be considered a “target” for cardiovascular therapy
here reversibility of dysfunction will be indicative of
mprovement in risk? This latter question was partly ad-
ressed in 400 postmenopausal women with hypertension
29). Event rates were seven-fold higher in those in whom
rachial artery flow-mediated vasodilation did not improve
y 10% compared with those who had improvement.
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Gender Differences in Ischemic Heart Disease February 7, 2006:66S–71Sinally, techniques for assessment of coronary and periph-
ral endothelial function have been invasive, laborious, and
echnically challenging, impeding their widespread deploy-
ent. Newer and more reproducible techniques, including
ulsatile arterial tonometry (30), which appears to correlate
ith risk factors and with coronary vascular endothelial
unction, need to be evaluated in future trials.
nflammation. Elevated circulating levels of inflammatory
arkers have been associated with incident cardiovascular
isease (31–33), linking chronic subclinical inflammation
nd atherosclerosis. In 14,719 apparently healthy women
nrolled in the Women’s Heath Initiative and followed for
ight years, a higher high-sensitivity C-reactive protein
CRP) level imposed a higher risk of CAD events during
ollow-up even after correction for the components of the
etabolic syndrome (34). The predictive value of inflam-
atory markers other than CRP has been investigated in
he WISE study cohorts. In over 700 women undergoing
ngiography, serum amyloid A levels were highly and
ndependently predictive of underlying CAD and of three-
ear outcomes, even after adjustment for CRP levels (35).
hen a larger panel of markers and a variable reduction
pproach was used to study a “proinflammatory” factor
oaded on interleukin-6, CRP, and serum amyloid A, a
pro- and antiinflammatory” factor loaded on interleukin-18
nd tumor necrosis factor-alpha, and an “immunosuppres-
ive” factor loaded on transforming growth factor-beta,
here was a significant increase in mortality with increases of
he “proinflammatory” factor (hazard ratio is seven-fold
reater in highest quartile compared to the lowest) (36).
uch an approach seeking a panel of informative biomarkers
hat will be prognostic in women is desirable.
besity, insulin resistance, and metabolic syndrome.
ne factor that threatens to dramatically increase CAD
revalence is the impending epidemic of obesity (37,38) that
ffects all segments of the population, including women,
hildren, and, most disturbingly, several minority ethnic
opulations (37,38). Although a large body of evidence
upports the relationship between obesity and CAD mor-
ality (39), the factors that mediate this increased risk are
omplex (40,41). The metabolic syndrome has recently been
efined to capture the cluster of characteristics associated
ith obesity and high CAD risk: abdominal adiposity, high
lood pressure, high blood glucose/insulin resistance, and an
ncreased triglycerides/high-density lipoprotein ratio. Al-
hough the precise criteria remain controversial and the
efinition remains a work in progress, there is a consensus
hat these elements are important features of the syndrome
42–49). Strikingly, the National Health and Nutrition
xamination Survey III data indicates that approximately
5% of the U.S. adult population 20 years or older and up
o 45% of the population over 50 years or older meets the
iagnostic criteria for the metabolic syndrome.
The WISE study has shed important light on the
revalence and impact of obesity, metabolic syndrome, and
hysical activity on cardiovascular risk in women admitted hor angiography. In over 750 women studied, 34% were
verweight, 42% were obese, and 58% had the metabolic
yndrome. The presence of obesity did not predict either the
nderlying severity of CAD or event-free survival, whereas
he presence of metabolic syndrome was associated with
orse CAD severity, and a two-fold higher odds of suffering
dverse CAD outcome during follow-up. This worse out-
ome was observed particularly in women with underlying
AD (50,51). Use of a self-reported index of physical
ctivity (Duke Activity Status Index [DASI]) revealed that
0% of women had low functional capacity (DASI scores
25, equivalent to 7 metabolic equivalents). The occurrence
f CAD and adverse events was correlated strongly with the
ASI and not with obesity, with each metabolic equivalent
ncrease in DASI associated with an 8% reduction in event
ate (52).
The mechanisms underlying obesity and metabolic
yndrome-related CAD risk have been studied in recent
ears. Not only is there an intimate association between
besity and insulin resistance (53,54), but also between
besity and the inflammatory markers fibrinogen and CRP
31,32,49,55–60). Waist circumference appears to correlate
trongly with CRP and fibrinogen levels (61) and is stronger
n women than in men (49), possibly owing to differing
istribution of body fat compartments (visceral vs. subcuta-
eous) between the sexes (62–65). The adipose tissue is an
ctive secretory organ that elaborates a variety of molecules
nown as adipocytokines, including tumor necrosis factor-
lpha, interleukin-6, leptin, adiponectin, and resistin
66,67). Inflammatory marker and cytokine levels appear to
redict future development of glucose intolerance (68,69)
nd vascular events (33,70). Subjects with the metabolic
yndrome have higher levels of oxidized low-density li-
oprotein, apolipoprotein B, urate, leukocytes, and erythro-
yte sedimentation rate, lower apolipoprotein A concentra-
ions, increased thrombotic tendencies, and reduced
brinolytic tendencies (55,71). Insulin resistance is associ-
ted with quantitative and qualitative changes in lipoprotein
articles and with endothelial activation (72,73). Other
athways up-regulated in the vasculature and adipose tissue
nclude the endothelin system (74,75) and the renin-
ngiotensin cascade (76–79). Whether these measures of
dipose tissue activation will be superior markers of cardio-
ascular risk over anatomic measures of obesity remains to
e determined.
thnicity and genetics. The morbidity and mortality from
therosclerosis, particularly stroke, is considerably higher in
frican Americans compared to Caucasians (80–84), indi-
ating potentially important genetic and environmental
ifferences in organ function, socioeconomic status, and
emodynamic responses to environmental challenges be-
ween the races (85–87). Several intriguing ethnic and
ender differences are evident in the prevalence of metabolic
yndrome, insulin resistance, type 2 diabetes, and cardiovas-
ular events. Black females have a larger waist and more
ypertension and hyperglycemia but a lower frequency of
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February 7, 2006:66S–71S Gender Differences in Ischemic Heart Diseaselevated triglyceride levels (37,38,88), leading to an under-
stimation of the prevalence of metabolic syndrome in black
omen. Insulin resistance is more common among black
ompared to white subjects for similar degree of adiposity
89,90), and African Americans have decreased insulin
ensitivity and differences in insulin secretion and hepatic
xtraction of insulin compared with Caucasians.
Beyond racial differences, the importance of family his-
ory in development of CAD and its adverse events high-
ights the modulatory influence of the individual’s genotype
o vascular disease susceptibility. Several genetic polymor-
hisms associated with CAD or CAD events have been
escribed in predominantly male populations. The WISE
tudy has begun exploring the relationship between geno-
ype and CAD incidence, and such efforts including larger
umbers of ethnic minorities are going to be essential in
nderstanding the influence of genetics on the vascular
henotype (91,92).
ascular repair. The classic paradigm for inception of
therosclerosis states that endothelial cell injury is the
timulus for atherosclerotic plaque development (93) where
eemingly disparate risk factors cause oxidative injury to the
ndothelium. Ultimately, the balance between injury and
epair is thought to be the major determinant of cardiovas-
ular disease progression, with endothelial progenitor cells
EPCs) playing an important role in vascular repair. Endo-
helial progenitor cell counts are lower in subjects with
ultiple risk factors, including diabetes and aging, and in
hose with endothelial dysfunction and CAD, indicating
hat increased oxidative stress may also lead to a depletion of
ysfunction of the circulating EPC pool (94–98). Thus,
PCs may provide a circulating pool of cells that could
onstitute a cellular “repair” mechanism at the sites of
ascular injury. Moreover, the observation that EPC activity
an be stimulated with statin therapy raises the possibility
hat risk improvement may be partly mediated by restora-
ion of EPC function (99–101).
Given that accelerated apoptosis of the injured endothe-
ium and defective repair by an exhausted or senescent
rogenitor pool is the new paradigm that defines athero-
clerotic disease prevalence and progression, it is timely to
nvestigate how these concepts apply to women at risk. The
PC release is stimulated by the menstrual cycle in pre-
enopausal women and it can be speculated that the lower
usceptibility to atherosclerotic disease in this subset is at
east partially explained by the increased availability of repair
echanisms. The observation that anemia is an important
isk factor in women from the WISE study is also intriguing
102), and raises the question as to whether anemia is a
anifestation of bone marrow hematopoietic progenitor cell
ool defect that extends to endothelial progenitors and
ignifies reduced repair function. These aspects will need to
e studied further.
onclusions. The understanding of the pathophysiology
f atherosclerotic disease and its progression in women has
enefited from trials like the WISE study and others thatave focused attention on the similarities and differences
ertaining to gender. It has also allowed us to introduce new
odalities to assess individual risk. Efforts to prospectively
est these emerging concepts and strategies in larger popu-
ations need to continue.
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